BioCentury
ARTICLE | Company News

Afferon, Icos deal

November 12, 2001 8:00 AM UTC

ICOS exclusively licensed from Afferon worldwide rights to RTX resiniferatoxin to treat urological disorders. ICOS will pay Afferon an upfront license fee, milestones and royalties, and will fund deve...